Trial Profile
A Multicenter, Double-Masked, Randomized, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Conbercept Intravitreal Injection in Subjects With Neovascular Age-Related Macular Degeneration (AMD) (PANDA-2)
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 15 Aug 2021
Price :
$35
*
At a glance
- Drugs Conbercept (Primary) ; Aflibercept
- Indications Wet age-related macular degeneration
- Focus Registrational; Therapeutic Use
- Acronyms PANDA-2
- Sponsors Chengdu Kanghong Biotech
- 21 Jun 2021 This trial has been discontinued in Denmark, according to European Clinical Trials Database record.
- 16 Jun 2021 Status changed from active, no longer recruiting to discontinued.
- 14 Jun 2021 This trial has been completed in Czechia, according to European Clinical Trials Database.